Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.56)
# 886
Out of 5,001 analysts
87
Total ratings
52.11%
Success rate
23.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $10.90 | +10.09% | 5 | Sep 15, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $510 → $475 | $403.00 | +17.87% | 19 | Sep 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $466.58 | +10.39% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $3.61 | -44.52% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $65.27 | +51.68% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $24.86 | +81.01% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.45 | +61.18% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $3.53 | +41.84% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.26 | +170.79% | 2 | Dec 11, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $38.91 | -10.05% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $405 → $360 | $455.97 | -21.05% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.27 | +57.42% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $14.70 | +124.57% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $47.74 | -20.40% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $29.66 | +169.72% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $7.48 | +140.64% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.93 | +536.13% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.18 | +466.34% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $29.06 | -17.41% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $14.56 | +106.11% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.58 | +118.58% | 1 | Feb 5, 2020 |
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $10.90
Upside: +10.09%
Vertex Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $510 → $475
Current: $403.00
Upside: +17.87%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $466.58
Upside: +10.39%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $3.61
Upside: -44.52%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $65.27
Upside: +51.68%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $24.86
Upside: +81.01%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.45
Upside: +61.18%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $3.53
Upside: +41.84%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.26
Upside: +170.79%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $38.91
Upside: -10.05%
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $455.97
Upside: -21.05%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.27
Upside: +57.42%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $14.70
Upside: +124.57%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $47.74
Upside: -20.40%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $29.66
Upside: +169.72%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $7.48
Upside: +140.64%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.93
Upside: +536.13%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.18
Upside: +466.34%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $29.06
Upside: -17.41%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $14.56
Upside: +106.11%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.58
Upside: +118.58%